News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
527,195 Results
Type
Article (44055)
Company Profile (124)
Press Release (483016)
Section
Business (148490)
Career Advice (2370)
Deals (28269)
Drug Delivery (100)
Drug Development (69277)
Employer Resources (147)
FDA (15864)
Job Trends (12002)
News (269235)
Policy (29882)
Tag
Academia (2289)
Africa (676)
Alliances (37382)
Alzheimer's disease (1216)
Approvals (15776)
Arizona (130)
Artificial intelligence (79)
Asia (30804)
Australia (5452)
Bankruptcy (305)
Best Places to Work (8993)
Biosimilars (70)
Biotechnology (76)
Breast cancer (71)
C2C Services and Suppliers (54641)
California (1834)
Canada (763)
Cancer (605)
Career advice (1977)
Cell therapy (155)
China (122)
Clinical research (54260)
Collaboration (171)
Colorado (72)
Compensation (111)
Connecticut (87)
COVID-19 (2519)
Cystic fibrosis (73)
Data (438)
Diabetes (99)
Diagnostics (5045)
Drug pricing (91)
Earnings (57313)
Employer resources (132)
Europe (74761)
Events (74955)
Executive appointments (156)
FDA (16156)
Florida (281)
Funding (158)
Gene therapy (114)
GLP-1 (593)
Government (3779)
Healthcare (14743)
Hotbed/Location (348297)
Illinois (206)
Indiana (120)
Infectious disease (2561)
Inflammatory bowel disease (87)
Interviews (442)
IPO (13780)
Job creations (3188)
Job search strategy (1657)
Kansas (75)
Layoffs (436)
Legal (6956)
Lung cancer (124)
Manufacturing (116)
Maryland (400)
Massachusetts (1510)
Medical device (11097)
Medtech (11100)
Mergers & acquisitions (14417)
Metabolic disorders (321)
Michigan (105)
Minnesota (178)
Neuroscience (1402)
New Jersey (565)
New York (571)
NextGen Class of 2024 (4979)
Non-profit (3167)
North Carolina (556)
Northern California (836)
Obesity (197)
Ohio (92)
Opinion (179)
Patents (79)
Pennsylvania (553)
People (42298)
Phase I (16108)
Phase II (23469)
Phase III (19303)
Pipeline (140)
Policy (73)
Postmarket research (2270)
Preclinical (6580)
Radiopharmaceuticals (197)
Rare diseases (152)
Real estate (4359)
Regulatory (20231)
Research institute (2054)
Resumes & cover letters (398)
South America (1039)
Southern California (748)
Startups (2854)
Texas (234)
United States (8115)
Vaccines (560)
Washington State (238)
Weight loss (179)
Date
Today (53)
Last 7 days (604)
Last 30 days (2417)
Last 365 days (32413)
2024 (24326)
2023 (35124)
2022 (45213)
2021 (48736)
2020 (45740)
2019 (36456)
2018 (27644)
2017 (28066)
2016 (26021)
2015 (28345)
2014 (22072)
2013 (18003)
2012 (19324)
2011 (19995)
2010 (18443)
527,195 Results for "edap tms s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
EDAP Reports First Quarter 2024 Financial Results
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the first quarter of 2024.
May 16, 2024
·
15 min read
Business
EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company’s European and Middle Eastern commercial leadership.
June 3, 2024
·
6 min read
Business
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16th, 2024.
May 2, 2024
·
1 min read
Business
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
EDAP TMS SA, the global leader in robotic energy-based therapies, reported unaudited financial results for the fourth quarter and full-year 2023.
March 27, 2024
·
19 min read
Business
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointment of Lance Willsey, M.S., M.D. to its Board of Directors.
December 6, 2023
·
3 min read
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE).
March 4, 2024
·
7 min read
Business
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
EDAP TMS SA, the global leader in robotic energy-based therapies, announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2023, before the markets open on Wednesday, March 27th, 2024.
March 13, 2024
·
1 min read
Business
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
EDAP TMS SA, the global leader in robotic energy-based therapies, announced preliminary Focal One placement results for the fourth quarter of calendar year 2023.
January 8, 2024
·
4 min read
Press Releases
EDAP Reports Second Quarter 2024 Financial Results
August 28, 2024
·
19 min read
Drug Development
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis.
February 1, 2024
·
6 min read
1 of 52,720
Next
